Literature DB >> 26396924

Diagnostic, prognostic and predictive value of MicroRNA-21 in breast cancer patients, their daughters and healthy individuals.

Ambreen Usmani1, Amir Ali Shoro2, Zahida Memon3, Mehvish Hussain4, Rehana Rehman5.   

Abstract

MicroRNA-21 (miR-21) located on 17q23.1 expressed in breast cancer has anti-apoptotic ability and causes tumor cell growth. It is also involved in functions such as signal transduction pathways effecting normal cell growth and differentiation. The primary objective of the study was to identify presence of miR-21 in the serum levels of stage III invasive ductal carcinoma patients and compare its expression with age matched healthy individuals and daughters of index cases. The secondary objective was to evaluate the significance of serum miR-21 gene expression with histologically proven estrogen receptor (ER), progesterone receptor (PR) and human epidermal growth factor receptor 2 (HER2) proteins. A total of 132 subjects were recruited: 50 (cases) of stage III invasive ductal carcinoma patients who had not undergone any chemotherapy or surgery were randomly picked with exclusion of females with other types of breast carcinoma. Age-matched, 50 healthy individuals (control A) were selected by purposive sampling after confirmation of no palpable lump/s in their breasts together with 32 daughters of index cases (control B). Serum tests were run on Real Time quantitative Reverse Transcription PCR, threshold cycle was determined and fold change calculated.Normality of continuous variables was assessed by Shapiro-Wilk's test, groups compared by student t-test, Mann-Whitney test and Fisher exact test, P-value ≤ 0.05 was considered significant. We observed that miR-21 was significantly higher in cases as compared to control A and B (P = 0.001) however control B showed significant gene expression as compared to control A (P = 0.001). The cases were also divided as positive or negative for ER, PR and HER2. High expression of miR-21 in females with stage III invasive ductal carcinoma had been calculated as compared to its age matched healthy subjects. It was observed that triple negative cases showed a greater expression of gene as compared to other groups (P = 0.001). Expression of miR-21 in daughters of the cases was significantly higher as compared to healthy controls but lesser than females with invasive intraductal carcinoma. This result strengthens the concept of inheritability of disease with prediction of miR-21 as a potentially strong diagnostic and prognostic biomarker of breast cancer.

Entities:  

Keywords:  ER; PR and HER-2; breast cancer; miR-21

Year:  2015        PMID: 26396924      PMCID: PMC4568784     

Source DB:  PubMed          Journal:  Am J Cancer Res        ISSN: 2156-6976            Impact factor:   6.166


  26 in total

1.  Analysis of relative gene expression data using real-time quantitative PCR and the 2(-Delta Delta C(T)) Method.

Authors:  K J Livak; T D Schmittgen
Journal:  Methods       Date:  2001-12       Impact factor: 3.608

2.  MicroRNA-21 regulates breast cancer invasion partly by targeting tissue inhibitor of metalloproteinase 3 expression.

Authors:  Bao Song; Chuanxi Wang; Jie Liu; Xingwu Wang; Liyan Lv; Ling Wei; Li Xie; Yan Zheng; Xianrang Song
Journal:  J Exp Clin Cancer Res       Date:  2010-03-27

3.  Trastuzumab after adjuvant chemotherapy in HER2-positive breast cancer.

Authors:  Martine J Piccart-Gebhart; Marion Procter; Brian Leyland-Jones; Aron Goldhirsch; Michael Untch; Ian Smith; Luca Gianni; Jose Baselga; Richard Bell; Christian Jackisch; David Cameron; Mitch Dowsett; Carlos H Barrios; Günther Steger; Chiun-Shen Huang; Michael Andersson; Moshe Inbar; Mikhail Lichinitser; István Láng; Ulrike Nitz; Hiroji Iwata; Christoph Thomssen; Caroline Lohrisch; Thomas M Suter; Josef Rüschoff; Tamás Suto; Victoria Greatorex; Carol Ward; Carolyn Straehle; Eleanor McFadden; M Stella Dolci; Richard D Gelber
Journal:  N Engl J Med       Date:  2005-10-20       Impact factor: 91.245

4.  miR-21-mediated tumor growth.

Authors:  M-L Si; S Zhu; H Wu; Z Lu; F Wu; Y-Y Mo
Journal:  Oncogene       Date:  2006-10-30       Impact factor: 9.867

5.  Serum circulating microRNA profiling for identification of potential breast cancer biomarkers.

Authors:  Fermín Mar-Aguilar; Jorge A Mendoza-Ramírez; Ismael Malagón-Santiago; Perla K Espino-Silva; Sandra K Santuario-Facio; Pablo Ruiz-Flores; Cristina Rodríguez-Padilla; Diana Reséndez-Pérez
Journal:  Dis Markers       Date:  2013       Impact factor: 3.434

Review 6.  MicroRNA expression in lymphoma.

Authors:  Charles H Lawrie
Journal:  Expert Opin Biol Ther       Date:  2007-09       Impact factor: 4.388

7.  Expression of miR-21 and its targets (PTEN, PDCD4, TM1) in flat epithelial atypia of the breast in relation to ductal carcinoma in situ and invasive carcinoma.

Authors:  Liqiang Qi; Joost Bart; Lu Ping Tan; Inge Platteel; Tineke van der Sluis; Sippie Huitema; Geert Harms; Li Fu; Harry Hollema; Anke van den Berg
Journal:  BMC Cancer       Date:  2009-05-28       Impact factor: 4.430

8.  MicroRNAs as Novel Biomarkers for Breast Cancer.

Authors:  H M Heneghan; N Miller; A J Lowery; K J Sweeney; M J Kerin
Journal:  J Oncol       Date:  2009-07-20       Impact factor: 4.375

9.  In vivo NCL targeting affects breast cancer aggressiveness through miRNA regulation.

Authors:  Flavia Pichiorri; Dario Palmieri; Luciana De Luca; Jessica Consiglio; Jia You; Alberto Rocci; Tiffany Talabere; Claudia Piovan; Alessandro Lagana; Luciano Cascione; Jingwen Guan; Pierluigi Gasparini; Veronica Balatti; Gerard Nuovo; Vincenzo Coppola; Craig C Hofmeister; Guido Marcucci; John C Byrd; Stefano Volinia; Charles L Shapiro; Michael A Freitas; Carlo M Croce
Journal:  J Exp Med       Date:  2013-04-22       Impact factor: 17.579

10.  Role of deregulated microRNAs in breast cancer progression using FFPE tissue.

Authors:  Liang Chen; Youhuai Li; Yebo Fu; Jin Peng; Meng-Hsuan Mo; Michael Stamatakos; Christine B Teal; Rachel F Brem; Alexander Stojadinovic; Michael Grinkemeyer; Timothy A McCaffrey; Yan-gao Man; Sidney W Fu
Journal:  PLoS One       Date:  2013-01-23       Impact factor: 3.240

View more
  12 in total

1.  MiR-654-5p attenuates breast cancer progression by targeting EPSTI1.

Authors:  Yu-Yan Tan; Xiao-Yun Xu; Jin-Feng Wang; Cheng-Wu Zhang; Sheng-Chu Zhang
Journal:  Am J Cancer Res       Date:  2016-01-15       Impact factor: 6.166

Review 2.  Applications of Extracellular RNAs in Oncology.

Authors:  Jonathan R Thompson; Jing Zhu; Deepak Kilari; Liang Wang
Journal:  Mol Diagn Ther       Date:  2017-02       Impact factor: 4.074

3.  Long noncoding RNA CNALPTC1 promotes cell proliferation and migration of papillary thyroid cancer via sponging miR-30 family.

Authors:  Cunrong Chen; Lili Zhou; Hui Wang; Junnian Chen; Wen Li; Wei Liu; Mingjie Shen; Hongzhou Liu; Xiaomin Fu
Journal:  Am J Cancer Res       Date:  2018-01-01       Impact factor: 6.166

4.  MicroRNA profiling associated with non-small cell lung cancer: next generation sequencing detection, experimental validation, and prognostic value.

Authors:  Sandra Gallach; Eloisa Jantus-Lewintre; Silvia Calabuig-Fariñas; David Montaner; Sergio Alonso; Rafael Sirera; Ana Blasco; Marta Usó; Ricardo Guijarro; Miguel Martorell; Carlos Camps
Journal:  Oncotarget       Date:  2017-06-22

5.  MiR-142 inhibits the development of cervical cancer by targeting HMGB1.

Authors:  Daqiong Jiang; Huiyan Wang; Zhuyan Li; Zhen Li; Xin Chen; Hongbing Cai
Journal:  Oncotarget       Date:  2017-01-17

6.  Prognostic role of microRNAs in breast cancer: A systematic review.

Authors:  Eleni Zografos; Flora Zagouri; Despoina Kalapanida; Roubini Zakopoulou; Anastasios Kyriazoglou; Kleoniki Apostolidou; Maria Gazouli; Meletios-Athanasios Dimopoulos
Journal:  Oncotarget       Date:  2019-12-24

7.  Early detection breast cancer: role of circulating plasma miRNA-21 expression as a potential screening biomarker

Authors:  Muhammad Noor Diansyah; Ami Ashariati Prayogo; Made Putra Sedana; Merlyna Savitri; Pradana Zaky Romadhon; Putu Niken Ayu Amrita; Andi Yasmin Wijaya; Winona May Hendrata; Ugroseno Yudho Bintoro
Journal:  Turk J Med Sci       Date:  2021-04-30       Impact factor: 0.973

Review 8.  New Concepts in Cancer Biomarkers: Circulating miRNAs in Liquid Biopsies.

Authors:  Erika Larrea; Carla Sole; Lorea Manterola; Ibai Goicoechea; María Armesto; María Arestin; María M Caffarel; Angela M Araujo; María Araiz; Marta Fernandez-Mercado; Charles H Lawrie
Journal:  Int J Mol Sci       Date:  2016-04-27       Impact factor: 5.923

Review 9.  Investigative and extrapolative role of microRNAs' genetic expression in breast carcinoma.

Authors:  Ambreen Usmani; Amir Ali Shoro; Bushra Shirazi; Zahida Memon
Journal:  Pak J Med Sci       Date:  2016 May-Jun       Impact factor: 1.088

10.  A Quasi-direct LC-MS/MS-based Targeted Proteomics Approach for miRNA Quantification via a Covalently Immobilized DNA-peptide Probe.

Authors:  Liang Liu; Qingqing Xu; Shuai Hao; Yun Chen
Journal:  Sci Rep       Date:  2017-07-18       Impact factor: 4.379

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.